Literature DB >> 18298473

Areca chewing in Xiangtan, Hunan province, China: interviews with chewers.

Xiaolin Zhang1, Chengjie Li, Qizhi Liao, Peter A Reichart.   

Abstract

BACKGROUND: To report on Areca chewing (AC) in Xiangtan, Hunan province, China, and to test the knowledge of chewers related to side effects of the habit.
METHODS: Interviews with 276 individuals were performed. A questionnaire including general data, chewing habits, educational level and knowledge about side effects were used. Data were analysed using SPSS. Chi-square test was used at a significance level of P < 0.05.
RESULTS: Around 257 individuals were chewers (male: 54.1%; female: 45.9%) and 19 were former chewers (male: 31.6%; female: 68.4%). Mean age of chewers was 36.1 years. Around 42.4% of chewers smoked; 58.0% had a drinking habit. Average period of chewing was 11.2 years. Around 88.3% of chewers did not include the nut (seed). Around 79.0% considered AC habits negative for general health and 85.2% for oral health.
CONCLUSIONS: Most respondents did not know that AC may induce oral submucous fibrosis and oral cancer. The 'betel quid' chewed in Xiangtan usually does not contain Areca 'nut' (seed, endosperm), but consists of the husk. As no studies on the chemical composition of the Areca husk have been published such investigations are urgently needed.

Entities:  

Mesh:

Year:  2008        PMID: 18298473     DOI: 10.1111/j.1600-0714.2008.00640.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  2 in total

1.  Mutational signatures and the genomic landscape of betel quid chewing-associated tongue carcinoma.

Authors:  Weilong Zhang; Mu Wang; Qifeng Wu; Qing Zhu; Yuchen Jiao; Yiming Zhu; Beibei Yang; Song Ni; Jianjun Yu; Hong Sun; Yi-Xin Zeng
Journal:  Cancer Med       Date:  2019-01-22       Impact factor: 4.452

2.  Selective apoptotic cell death effects of oral cancer cells treated with destruxin B.

Authors:  Rosa Huang Liu; Shih-Pin Chen; Tsong-Ming Lu; Wei-Yu Tsai; Chung-Hung Tsai; Chi-Chiang Yang; Yew-Min Tzeng
Journal:  BMC Complement Altern Med       Date:  2014-06-28       Impact factor: 3.659

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.